Cargando…

Association between Serum Concentrations of Apolipoprotein A-I (ApoA-I) and Alzheimer’s Disease: Systematic Review and Meta-Analysis

Background: A wealth of experimental and epidemiological evidence suggest that Apolipoprotein A-I (ApoA-I), the main protein constituent of high-density lipoprotein (HDL), may protect against Alzheimer disease (AD). To investigate this potential role, we conducted a meta-analysis of the published st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zuin, Marco, Cervellati, Carlo, Trentini, Alessandro, Passaro, Angelina, Rosta, Valentina, Zimetti, Francesca, Zuliani, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229134/ https://www.ncbi.nlm.nih.gov/pubmed/34071695 http://dx.doi.org/10.3390/diagnostics11060984

Ejemplares similares

Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer
por: Georgila, Konstantina, et al.
Publicado: (2019)

Increased blood BACE1 activity as a potential common pathogenic factor of vascular dementia and late onset Alzheimer's disease
por: Zuliani, Giovanni, et al.
Publicado: (2020)

Sex Difference Impacts on the Relationship between Paraoxonase-1 (PON1) and Type 2 Diabetes
por: Rosta, Valentina, et al.
Publicado: (2020)

Lipoprotein-Associated Phospholipase A2 Activity as Potential Biomarker of Vascular Dementia
por: Zuliani, Giovanni, et al.
Publicado: (2023)

Iowa Mutant Apolipoprotein A-I (ApoA-I(Iowa)) Fibrils Target Lysosomes
por: Kameyama, Hirokazu, et al.
Publicado: (2016)

Viral Load Difference between Symptomatic and Asymptomatic COVID-19 Patients: Systematic Review and Meta-Analysis
por: Zuin, Marco, et al.
Publicado: (2021)

Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis
por: Zuin, Marco, et al.
Publicado: (2022)

Risk of dementia in patients with atrial fibrillation: Short versus long follow‐up. A systematic review and meta‐analysis
por: Zuin, Marco, et al.
Publicado: (2021)

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent
por: Lebherz, Corinna, et al.
Publicado: (2007)

SIDT2 Associates with Apolipoprotein A1 (ApoA1) and Facilitates ApoA1 Secretion in Hepatocytes
por: Sampieri, Alicia, et al.
Publicado: (2023)

The unsolved mystery of apoA-I recycling in adipocyte
por: Wang, Shuai, et al.
Publicado: (2016)

Comparison of Apolipoprotein (apoB/apoA-I) and Lipoprotein (Total Cholesterol/HDL) Ratio Determinants. Focus on Obesity, Diet and Alcohol Intake
por: Tognon, Gianluca, et al.
Publicado: (2012)

Brain ApoA-I, ApoJ and ApoE Immunodetection in Cerebral Amyloid Angiopathy
por: Camacho, Jessica, et al.
Publicado: (2019)

Testing a Combination of Markers of Systemic Redox Status as a Possible Tool for the Diagnosis of Late Onset Alzheimer's Disease
por: Zuliani, Giovanni, et al.
Publicado: (2018)

Autophagy Alteration in ApoA-I Related Systemic Amyloidosis
por: Del Giudice, Rita, et al.
Publicado: (2022)

HDL Proteome and Alzheimer’s Disease: Evidence of a Link
por: Marsillach, Judit, et al.
Publicado: (2020)

ApoA-I mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer
por: Cedó, Lídia, et al.
Publicado: (2016)

Effects of Individual Amino Acids on PPARα Transactivation, mTORC1 Activation, ApoA-I Transcription and pro-ApoA-I Secretion
por: Tayyeb, Jehad Z., et al.
Publicado: (2022)

Human Serum Amyloid a Impaired Structural Stability of High-Density Lipoproteins (HDL) and Apolipoprotein (Apo) A-I and Exacerbated Glycation Susceptibility of ApoA-I and HDL
por: Cho, Kyung-Hyun
Publicado: (2022)

Different Functional and Structural Characteristics between ApoA-I and ApoA-4 in Lipid-Free and Reconstituted HDL State: ApoA-4 Showed Less Anti-Atherogenic Activity
por: Yoo, Jeong-Ah, et al.
Publicado: (2015)

Human apoA-I[Lys107del] mutation affects lipid surface behavior of apoA-I and its ability to form large nascent HDL
por: Gorshkova, Irina N., et al.
Publicado: (2022)

An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration
por: Chen, Xun, et al.
Publicado: (2009)

HDL-apoA-I Exchange: Rapid Detection and Association with Atherosclerosis
por: Borja, Mark S., et al.
Publicado: (2013)

Effect of apoA-I on cholesterol release and apoE secretion in human mature adipocytes
por: Bencharif, Karima, et al.
Publicado: (2010)

Connection between the Altered HDL Antioxidant and Anti-Inflammatory Properties and the Risk to Develop Alzheimer's Disease: A Narrative Review
por: Zimetti, Francesca, et al.
Publicado: (2021)

Fast skeletal troponin I, but not the slow isoform, is increased in patients under statin therapy: a pilot study
por: Trentini, Alessandro, et al.
Publicado: (2018)

Serum zonulin levels are increased in Alzheimer’s disease but not in vascular dementia
por: Boschetti, Elisa, et al.
Publicado: (2023)

HDL/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2015)

Increased Serum Beta-Secretase 1 Activity is an Early Marker of Alzheimer’s Disease
por: Nicsanu, Roland, et al.
Publicado: (2022)

Current and Emerging Reconstituted HDL-apoA-I and HDL-apoE Approaches to Treat Atherosclerosis
por: Valanti, Eftaxia-Konstantina, et al.
Publicado: (2018)

ApoA-I-Mediated Lipoprotein Remodeling Monitored with a Fluorescent Phospholipid
por: Neufeld, Edward B., et al.
Publicado: (2019)

Association of serum apoA-I with in-stent restenosis in coronary heart disease
por: Wang, Xin, et al.
Publicado: (2022)

Frontier on Alzheimer’s Disease
por: Cervellati, Carlo, et al.
Publicado: (2023)

Potential of Apolipoprotein A1 (ApoA1) for Detecting Liver Cirrhosis and Hepatocellular Carcinoma
por: Gumilas, Nur Signa Aini, et al.
Publicado: (2022)

Single nucleotide polymorphisms of APOA1 gene and their relationship with serum apolipoprotein A-I concentrations in the native population of Assam
por: Bora, Kaustubh, et al.
Publicado: (2015)

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist
por: McLure, Kevin G., et al.
Publicado: (2013)

Effect of apoA-I PEGylation on the Biological Fate of Biomimetic High-Density Lipoproteins
por: Pedersbæk, Dennis, et al.
Publicado: (2020)

ApoA-I mimetics reduce systemic and gut inflammation in chronic treated HIV
por: Daskou, Maria, et al.
Publicado: (2022)

Sex difference: an important issue to consider in epidemiological and clinical studies dealing with serum paraoxonase-1
por: Trentini, Alessandro, et al.
Publicado: (2019)

Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I)
por: Michael Gibson, C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pl89a5chjjrl4vkmqv8av9rfp3